ticlopidine has been researched along with Hepatic Insufficiency in 2 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Hepatic Insufficiency: Conditions in which the LIVER functions fall below the normal ranges. Severe hepatic insufficiency may cause LIVER FAILURE or DEATH. Treatment may include LIVER TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Many medications (warfarin, heparin, clopidogrel) or physiological factors (elevated International Normalized Ratio [INR], thrombocytopenia, uremia) increase the risk for bleeding." | 3.79 | The safety of thoracentesis in patients with uncorrected bleeding risk. ( Araujo, KL; Argento, AC; Murphy, TE; Pisani, MA; Puchalski, JT, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Puchalski, JT | 1 |
| Argento, AC | 1 |
| Murphy, TE | 1 |
| Araujo, KL | 1 |
| Pisani, MA | 1 |
| Lee, SA | 1 |
| Suh, JW | 1 |
| Park, JJ | 1 |
| Yoon, CH | 1 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Chae, IH | 1 |
| Kim, HS | 1 |
| Kim, SH | 1 |
| Choi, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Vacuum vs Manual Drainage During Unilateral Thoracentesis: A Randomized Trial[NCT03496987] | 100 participants (Actual) | Interventional | 2015-12-01 | Completed | |||
| A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment[NCT02294643] | Phase 3 | 220 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients who had procedure termination prior to complete evacuation of the pleural contents (usually as a result of refractory pain or another symptom that the patient perceived). (NCT03496987)
Timeframe: 5-20 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Manual Drainage | 1 |
| Vacuum Bottle Drainage | 8 |
"Difference in pain between pre-procedural pain and during drainage pain as measured as the difference between a pre-procedural NPSS pain score (range from 0 (no pain) to 10 (maximum pain)). This was asked again during drainage and the difference between the two was recorded. The values ranged from -10 to 10 (with a more negative number representing a decrease in pain and a more positive number representing an increase in pain)~The scale used is called The Numeric Pain Rating Scale. With ratings from 0-10. Zero is the least amount of pain experienced while 10 is the worst pain possible." (NCT03496987)
Timeframe: 5-20 minutes
| Intervention | Pre-post NPRS Pain Scale Score (Mean) |
|---|---|
| Manual Drainage | 0.53 |
| Vacuum Bottle Drainage | 1.43 |
Actual time of drainage in seconds for each patient. (NCT03496987)
Timeframe: 5-20 minutes
| Intervention | seconds (Mean) |
|---|---|
| Manual Drainage | 498.5 |
| Vacuum Bottle Drainage | 318.6 |
Volume of effusion drained (in mL) (NCT03496987)
Timeframe: <20 minutes
| Intervention | milliters (Mean) |
|---|---|
| Manual Drainage | 1023 |
| Vacuum Bottle Drainage | 1143 |
Clinical etiology of effusion (NCT03496987)
Timeframe: <7 days
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Malignant | Paramalignant | Heart Failure | Hepatic Hydrothorax | Post-Cardiothoracic Procedure | Parapneumonic | Unknown | |
| Manual Drainage | 13 | 7 | 7 | 3 | 13 | 3 | 3 |
| Vacuum Bottle Drainage | 8 | 2 | 8 | 5 | 17 | 2 | 8 |
Any complications that occur as a direct result of the procedure. We tracked patients for 7 days after the procedure to capture any complications (which is typical clinical practice) (NCT03496987)
Timeframe: <7 days
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Pneumothorax | Hemothorax | Clinically Significant Pulmonary Edema | |
| Manual Drainage | 0 | 0 | 0 |
| Vacuum Bottle Drainage | 3 | 1 | 1 |
1 trial available for ticlopidine and Hepatic Insufficiency
| Article | Year |
|---|---|
Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus; Drug Therapy, Co | 2015 |
1 other study available for ticlopidine and Hepatic Insufficiency
| Article | Year |
|---|---|
The safety of thoracentesis in patients with uncorrected bleeding risk.
Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Disorders; Clopidogrel; Cohort Studies; D | 2013 |